FDA 510(k) audit finds that 80% of NSE rejections are due to insufficient performance data
This article was originally published in RAJ Devices
Executive Summary
Around 80% of the 510(k) marketing applications for medical devices that the US Food and Drug Administration rejects after reaching a "not substantially equivalent" (NSE) determination are turned down because the sponsor has failed to submit sufficient performance data1.